Sensitization of Human Colon Cancer Cells to TRAIL-Mediated Apoptosis

Journal of Gastrointestinal Surgery

Volumn 5, Issue 1, 2001, Pages 56-65

  Hernandez, Ambrosio ^a   Wang, Qingding ^a   Schwartz, Stephanie A ^a   Evers, B Mark ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

Actinomycin D; Apoptosis; Colon cancers; Cycloheximide; FLIP; TRAIL

Indexed keywords

ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; APOPTOSIS REGULATORY PROTEIN; CASP8 PROTEIN, HUMAN; CASP9 PROTEIN, HUMAN; CASPASE; CASPASE 8; CASPASE 9; CYCLOHEXIMIDE; DACTINOMYCIN; MEMBRANE PROTEIN; PROTEIN SYNTHESIS INHIBITOR; RNA; TNFSF10 PROTEIN, HUMAN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

APOPTOSIS; ARTICLE; CELL CULTURE; COLON TUMOR; DRUG EFFECT; DRUG RESISTANCE; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; HUMAN; LIVER TUMOR; METASTASIS; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BLOTTING, WESTERN; CASPASE 8; CASPASE 9; CASPASES; COLONIC NEOPLASMS; CYCLOHEXIMIDE; DACTINOMYCIN; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIVER NEOPLASMS; MEMBRANE GLYCOPROTEINS; PROTEIN SYNTHESIS INHIBITORS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0035228470     PISSN: 1091255X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1091-255X(01)80014-7     Document Type: Article

References (50)

1. Steller H. Mechanisms and genes of cellular suicide. Science 1995;267:1445-1449.
2. Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science 1995;267:1456-1462.
3. Nagata S. Apoptosis by death factor. Cell 1997;88:355-365.
4. Lotz M, Setareh M, von Kempis J, Schwarz H. The nerve growth factor/tumor necrosis factor receptor family. J Leukoc Biol 1996;60:1-7.
5. Armitage RJ. Tumor necrosis factor receptor superfamily members and their ligands. Curr Opin Immunol 1994;6:407-413.
6. Smith CA, Farrah T, Goodwin RG. The TNF receptor superfamily of cellular and viral proteins: Activation, costimulation, and death. Cell 1994;76:959-962.
7. Kayagaki N, Yamaguchi N, Nakayama M, Takeda K, Akiba H, Tsutsui H, Okamura H, Nakanishi K, Okumura K, Yagita H. Expression and function of TNF-related apoptosis-inducing ligand on murine activated NK cells. J Immunol 1999;163: 1906-1913.
8. Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, Sutherland GR, Smith TD, Rauch C, Smith CA, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995;3:673-682.
9. Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 1996;271:12687-12690.
10. Hersey P. Impediments to successful immunotherapy. Pharmacol Ther 1999;81:111-119.
11. Frank S, Kohler U, Schackert G, Schackert HK. Expression of TRAIL and its receptors in human brain tumors. Biochem Biophys Res Commun 1999;257:454-459.
12. Ozoren N, Fisher MJ, Kim K, Liu CX, Genin A, Shifman Y, Dicker DT, Spinner NB, Lisitsyn NA, El-Deiry WS. Homozygous deletion of the death receptor DR4 gene in a nasopharyngeal cancer cell line is associated with TRAIL resistance. Int J Oncol 2000;16:917-925.
13. Zhang XD, Franco AV, Nguyen T, Gray CP, Hersey P. Differential localization and regulation of death and decoy receptors for TNF-related apoptosis-inducing ligand (TRAIL) in human melanoma cells. J Immunol 2000;164:3961-3970.
14. Zhang XD, Franco A, Myers K, Gray C, Nguyen T, Hersey P. Relation of TNF-related apoptosis-inducing ligand (TRAIL) receptor and FLICE-inhibitory protein expression to TRAIL-induced apoptosis of melanoma. Cancer Res 1999;59:2747-2753.
15. Thome M, Schneider P, Hofmann K, Fickenscher H, Meinl E, Neipel F, Mattmann C, Burns K, Bodmer JL, Schroter M, Scaffidi C, Krammer PH, Peter ME, Tschopp J. Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors. Nature 1997;386:517-521.
16. Hu S, Vincenz C, Buller M, Dixit VM. A novel family of viral death effector domain-containing molecules that inhibit both CD-95- and tumor necrosis factor receptor-1-induced apoptosis. J Biol Chem 1997;272:9621-9624.
17. Bertin J, Armstrong RC, Ottilie S, Martin DA, Wang Y, Banks S, Wang GH, Senkevich TG, Alnemri ES, Moss B, Lenardo MJ, Tomaselli KJ, Cohen JI. Death effector domain-containing herpesvirus and poxvirus proteins inhibit both Fas- and TNFR1-induced apoptosis. Proc Natl Acad Sci USA 1997;94:1172-1176.
18. Leverkus M, Neumann M, Mengling T, Rauch CT, Brocker EB, Krammer PH, Walczak H. Regulation of tumor necrosis factor-related apoptosis-inducing ligand sensitivity in primary and transformed human keratinocytes. Cancer Res 2000;60: 553-559.
19. Algeciras-Schimnich A, Griffith TS, Lynch DH, Paya CV. Cell cycle-dependent regulation of FLIP levels and susceptibility to Fas-mediated apoptosis. J Immunol 1999;162:5205-5211.
20. Refaeli Y, Van Parijs L, London CA, Tschopp J, Abbas AK. Biochemical mechanisms of IL-2-regulated Fas-mediated T cell apoptosis. Immunity 1998;8:615-623.
21. Hernandez A, Evers BM. Assessment of differential gene expression patterns in human colon cancers. Ann Surg 2000 (in press).
22. Sheridan JP, Marsters SA, Pitti RM, Gurney A, Skubatch M, Baldwin D, Ramakrishnan L, Gray CL, Baker K, Wood WI, Goddard AD, Godowski P, Ashkenazi A. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 1997;277:818-821.
23. Pan G, Ni J, Wei YF, Yu G, Gentz R, Dixit VM. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 1997;277:815-818.
24. Kothny-Wilkes G, Kulms D, Poppelmann B, Luger TA, Kubin M, Schwarz T. Interleukin-1 protects transformed keratinocytes from tumor necrosis factor-related apoptosisinducing ligand. J Biol Chem 1998;273:29247-29253.
25. Scaffidi C, Schmitz I, Krammer, PH, Peter ME. The role of c-FLIP in modulation of CD95-induced apoptosis. J Biol Chem 1999;274:1541-1548.
26. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248-254.
27. Scharnhorst V, Dekker P, van der Eb AJ, Jochemsen AG. Physical interaction between Wilms tumor 1 and p73 proteins modulates their functions. J Biol Chem 2000;275:10202-10211.
28. Atarashi Y, Kanaya H, Whieside TL. A modified JAM assay detects apoptosis induced in activated lymphocytes by FasL + human adherent tumor cells [letter]. J Immunol Methods 2000;233:179-183.
29. Bohm C, Hanski ML, Gratchev A, Mann B, Moyer MP, Riecken EO, Hanski C. A modification of the JAM test is necessary for a correct determination of apoptosis induced by FasL+ adherent tumor cells. J Immunol Methods 1998; 217:71-78.
30. Matzinger P. The JAM test. A simple assay for DNA fragmentation and cell death. J Immunol Methods 1991;145:185-192.
31. Martinez-Lorenzo MJ, Alava MA, Gamen S, Kim KJ, Chuntharapai A, Pineiro A, Naval J, Anel A. Involvement of APO2 ligand/TRAIL in activation-induced death of Jurkat and human peripheral blood T cells. Eur J Immunol 1998;28: 2714-2725.
32. Monleon I, Martinez-Lorenzo MJ, Anel A, Lasierra P, Larrad L, Pineiro A, Naval J, Alava MA. CD59 cross-linking induces secretion of APO2 ligand in overactivated human T cells. Eur J Immunol 2000;30:1078-1087.
33. Johnsen AC, Haux J, Steinkjer B, Nonstad U, Egeberg K, Sundan A, Ashkenazi A, Espevik T. Regulation of APO-2 ligand/trail expression in NK cells-involvement in NK cell-mediated cytotoxicity. Cytokine 1999;11:664-672.
34. Griffith TS, Rauch CT, Smolak PJ, Waugh JY, Boiani N, Lynch DH, Smith CA, Goodwin RG, Kubin MZ. Functional analysis of TRAIL receptors using monoclonal antibodies. J Immunol 1999;162:2597-2605.
35. Thomas WD, Hersey P. TNF-related apoptosis-inducing ligand (TRAIL) induces apoptosis in Fas ligand-resistant melanoma cells and mediates CD4 T cell killing of target cells. J Immunol 1998;161:2195-2200.
36. Jo M, Kim TH, Seol DW, Esplen JE, Dorko K, Billiar TR, Strom SC. Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat Med 2000;6:564-567.
37. Kim K, Fisher MJ, Xu SQ, el-Deiry WS. Molecular determinants of response to TRAIL in killing of normal and cancer cells. Clin Cancer Res 2000;6:335-346.
38. Mori S, Murakami-Mori K, Nakamura S, Ashkenazi A, Bonavida B. Sensitization of AIDS-Kaposi's sarcoma cells to Apo-2 ligand-induced apoptosis by actinomycin D. J Immunol 1999;162:5616-5623.
39. Nagane M, Pan G, Weddle JJ, Dixit VM, Cavenee WK, Huang HJ. Increased death receptor 5 expression by chemo therapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis inducing ligand in vitro and in vivo. Cancer Res 2000;60: 847-853.
40. Mizutani Y, Yoshida O, Miki T, Bonavida B. Synergistic cytotoxicity and apoptosis by Apo-2 ligand and adriamycin against bladder cancer cells. Clin Cancer Res 1999;5:2605-2612.
41. Chinnaiyan AM, Prasad U, Shankar S, Hamstra DA, Shanaiah M, Chenevert TL, Ross BD, Rehemtulla A. Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy. Proc Natl Acad Sci U S A 2000;97:1754-1759.
42. Gliniak B, Le T. Tumor necrosis factor-related apoptosis-inducing ligand's antitumor activity in vivo is enhanced by the chemotherapeutic agent CPT-11. Cancer Res 1999;59:6153-6158.
43. MacFarlane M, Ahmad M, Srinivasula SM, FernandesAlnemri T, Cohen GM, Alnemri ES. Identification and molecular cloning of two novel receptors for the cytotoxic ligand TRAIL. J Biol Chem 1997;272:25417-25420.
44. Griffith TS, Chin WA, Jackson GC, Lynch DH, Kubin MZ. Intracellular regulation of TRAIL-induced apoptosis in hu-man melanoma cells. J Immunol 1998;161:2833-2840.
45. Kordes U, Krappmann D, Heissmeyer V, Ludwig WD, Scheidereit C. Transcription factor NF-KB is constitutively activated in acute lymphoblastic leukemia cells. Leukemia 2000; 14:399-402.
46. Jo H, Zhang R, Zhang H, McKinsey TA, Shao J, Beauchamp RD, Ballard DW, Liang P. NF-κB is required for H-ras oncogene induced abnormal cell proliferation and tumorigenesis. Oncogene 2000;19:841-849.
47. Ogilvy S, Metcalf D, Print CG, Bath ML, Harris AW, Adams JM. Constitutive Bcl-2 expression throughout the hematopoietic compartment affects multiple lineages and enhances progenitor cell survival. Proc Nad Acad Sci USA 1999;96: 14943-14948.
48. Dragovich T, Rudin CM, Thompson CB. Signal transduction pathways that regulate cell survival and cell death. Oncogene 1998;17:3207-3213.
49. Li F, Ambrosini G, Chu EY, Plescia J, Tognin S, Marchisio PC, Altieri DC. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 1998;396:580-584.
50. Adida C, Crotty PL, McGrath J, Berrebi D, Diebold J, Altieri DC. Developmentally regulated expression of the novel cancer anti-apoptosis gene survivin in human and mouse differentiation. Am J Pathol 1998;152:43-49.